CN119677528A - 用于治疗实体癌的组合物和方法 - Google Patents

用于治疗实体癌的组合物和方法 Download PDF

Info

Publication number
CN119677528A
CN119677528A CN202380033790.0A CN202380033790A CN119677528A CN 119677528 A CN119677528 A CN 119677528A CN 202380033790 A CN202380033790 A CN 202380033790A CN 119677528 A CN119677528 A CN 119677528A
Authority
CN
China
Prior art keywords
cancer
composition
bladder
glycine
myeloperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033790.0A
Other languages
English (en)
Chinese (zh)
Inventor
R·C·爱伦
J·T·小斯蒂芬斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exoxemis Inc
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of CN119677528A publication Critical patent/CN119677528A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380033790.0A 2022-04-13 2023-04-12 用于治疗实体癌的组合物和方法 Pending CN119677528A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263330553P 2022-04-13 2022-04-13
US63/330,553 2022-04-13
PCT/US2023/018289 WO2023200842A1 (en) 2022-04-13 2023-04-12 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
CN119677528A true CN119677528A (zh) 2025-03-21

Family

ID=88330172

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033790.0A Pending CN119677528A (zh) 2022-04-13 2023-04-12 用于治疗实体癌的组合物和方法

Country Status (10)

Country Link
US (1) US20250332226A1 (https=)
EP (1) EP4507793A1 (https=)
JP (1) JP2025512366A (https=)
KR (1) KR20250004257A (https=)
CN (1) CN119677528A (https=)
AU (1) AU2023252830A1 (https=)
CA (1) CA3246603A1 (https=)
IL (1) IL316053A (https=)
MX (1) MX2024012316A (https=)
WO (1) WO2023200842A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486408A (en) * 1981-04-07 1984-12-04 Kiel Johnathan L Insoluble crosslinked cytotoxic oxidase-peroxidase system
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
WO2013009910A2 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
CA3196357A1 (en) * 2020-11-11 2022-05-19 Robert C. Allen Compositions and methods for treating solid cancer

Also Published As

Publication number Publication date
EP4507793A1 (en) 2025-02-19
AU2023252830A1 (en) 2024-10-10
IL316053A (en) 2024-11-01
WO2023200842A1 (en) 2023-10-19
KR20250004257A (ko) 2025-01-07
MX2024012316A (es) 2024-11-08
US20250332226A1 (en) 2025-10-30
JP2025512366A (ja) 2025-04-17
CA3246603A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US20100178273A1 (en) Methods and compositions for treating mucositis
JP2010148509A (ja) アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法
CN103764137A (zh) 嗜伊红粒细胞过氧化物酶组合物和它们的使用方法
EP3442564B1 (en) Composition of proenzymes for cancer treatment
CN116710121A (zh) 用于治疗实体癌的组合物和方法
EP0062434B1 (en) Insoluble crosslinked cytotoxic oxidase-peroxidase system
Agostinelli et al. Hyperthermia enhances cytotoxicity of amine oxidase and spermine on drug-resistant LoVo colon adenocarcinoma cells
CN119677528A (zh) 用于治疗实体癌的组合物和方法
JP2005538709A (ja) アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法
EP3710033A1 (en) Nuclear-targeted dna repair enzymes and methods of use
US20060275279A1 (en) Methods for dissolving cystine stones and reducing cystine in urine
JP2006505290A (ja) 抗酸化医薬化合物、ポリペプチドの産生方法、治療方法
HK40098212A (zh) 用於治疗实体癌的组合物和方法
WO2009149201A1 (en) Methods of treatment for pulmonary fibrosis
JP3227673B2 (ja) 膵炎予防治療薬
EP3373956B1 (en) Proenzyme composition
US12419938B2 (en) Proenzyme composition
CN105477627B (zh) 治疗前列腺癌的组合物及其用途
WO2002040498A2 (en) Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides
WO2023144387A1 (en) Antibacterial properties of polypeptides with nlpc/p60 domains
CA3003835C (en) Proenzyme composition
CA2525672A1 (en) Use of peroxovanadium compounds as tumour cell growth suppressor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination